Jenna K. Dowhaniuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jenna K. Dowhaniuk has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Allan Puran1 shared publication
- Alyssa V. Ramuscak
The Hospital for Sick Children, Department of Pediatrics, Division of Gastroenterology, Hepatology & Nutrition, Toronto, Ontario, Canada
1 shared publication - Anne F. Klassen
Department of Pediatrics, McMaster University, Hamilton, Canada
1 shared publication - Catharine M. Walsh
Division of Gastroenterology, Hepatology and Nutrition and the SickKids Research and Learning Institutes, The Hospital for Sick Children
1 shared publication - Christina Grant
Division of Adolescent Medicine, Department of Pediatrics, McMaster University, Hamilton, ON L8S 4K1, Canada
1 shared publication Dawn M. E. Bowdish
Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Development of a Patient-Reported Outcome Instrument for Children and Youth With Celiac Disease (CELIAC-Q Kids): Protocol for an International Phase 1 Mixed Methods Study (Preprint)
BACKGROUND A critical limitation in outcome assessment for celiac disease (CeD) is the lack of a pediatric-specific patient-reported outcome (PRO) instrument to capture disease- and treatment-related outcomes and experiences of health and health care from the patient perspective. OBJECTIVE This protocol describes phase 1 of a multiphase mixed methods study to develop the CELIAC-Q Kids, a cross-cultural, internationally applicable PRO instrument for children and youth aged 8 to 18 years with CeD. METHODS The CELIAC-Q Kids will be developed using a multistage mixed methods approach consistent with best practices for PRO instrument development. First, a scoping review identifying concepts previously measured in individuals with CeD informed the development of a preliminary conceptual framework. Second, concept elicitation interviews with children and youth aged 8 to 18 years with CeD and their caregivers will be conducted to identify concepts of importance to patients. Qualitative data will be analyzed using interpretive description to refine the conceptual framework and generate an item pool and preliminary scales. Third, cognitive debriefing interviews with children and youth, together with multidisciplinary expert clinician input from participating international centers, will be used to iteratively refine items and scales. Finally, the field-test version of the CELIAC-Q Kids will be translated using rigorous, standardized methods in preparation for an international field-test study. Ethics approval has been obtained from the research ethics boards at all participating sites. RESULTS The study was first funded in 2020, with additional funding received in 2025. Recruitment for the concept elicitation interviews began in July 2020, and data collection was completed in June 2024 with 25 participants. As of September 2026, cognitive debriefing interviews are ongoing. The field-test version of the CELIAC-Q Kids is expected to be complete by December 2026, translation and cultural adaptation are planned for 2027, and phase 1 results are expected to be published in 2027 CONCLUSIONS At the end of this phase, a conceptual framework and set of scales capturing disease- and treatment-related outcomes and experiences relevant to pediatric CeD will be developed and ready for field testing. An integrated knowledge translation approach will engage patients, families, and clinicians throughout the study, and findings will be disseminated through peer-reviewed publications and scientific conferences. CLINICALTRIAL ClinicalTrials.gov NCT05548166
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment of a Patient-Reported Outcome Instrument for Children and Youth With Celiac Disease (CELIAC-Q Kids): Protocol for an International Phase 1 Mixed Methods Study (Preprint)
BACKGROUND A critical limitation in outcome assessment for celiac disease (CeD) is the lack of a pediatric-specific patient-reported outcome (PRO) instrument to capture disease- and treatment-related outcomes and experiences of health and health care from the patient perspective. OBJECTIVE This protocol describes phase 1 of a multiphase mixed methods study to develop the CELIAC-Q Kids, a cross-cultural, internationally applicable PRO instrument for children and youth aged 8 to 18 years with CeD. METHODS The CELIAC-Q Kids will be developed using a multistage mixed methods approach consistent with best practices for PRO instrument development. First, a scoping review identifying concepts previously measured in individuals with CeD informed the development of a preliminary conceptual framework. Second, concept elicitation interviews with children and youth aged 8 to 18 years with CeD and their caregivers will be conducted to identify concepts of importance to patients. Qualitative data will be analyzed using interpretive description to refine the conceptual framework and generate an item pool and preliminary scales. Third, cognitive debriefing interviews with children and youth, together with multidisciplinary expert clinician input from participating international centers, will be used to iteratively refine items and scales. Finally, the field-test version of the CELIAC-Q Kids will be translated using rigorous, standardized methods in preparation for an international field-test study. Ethics approval has been obtained from the research ethics boards at all participating sites. RESULTS The study was first funded in 2020, with additional funding received in 2025. Recruitment for the concept elicitation interviews began in July 2020, and data collection was completed in June 2024 with 25 participants. As of September 2026, cognitive debriefing interviews are ongoing. The field-test version of the CELIAC-Q Kids is expected to be complete by December 2026, translation and cultural adaptation are planned for 2027, and phase 1 results are expected to be published in 2027 CONCLUSIONS At the end of this phase, a conceptual framework and set of scales capturing disease- and treatment-related outcomes and experiences relevant to pediatric CeD will be developed and ready for field testing. An integrated knowledge translation approach will engage patients, families, and clinicians throughout the study, and findings will be disseminated through peer-reviewed publications and scientific conferences. CLINICALTRIAL ClinicalTrials.gov NCT05548166
- Open Access
Silent Struggles: Uncovering Mental Health Burdens in Adolescents with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis—A Retrospective Chart Review
Background/Objectives: Juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) are chronic autoimmune conditions that impact the physical and psychological well-being of pediatric patients. While previous studies have shown a high prevalence of mental health challenges among youth with chronic conditions, the prevalence of mental health issues in Canadian pediatric patients with JIA and IBD remains unclear. We aimed to estimate the prevalence of documented mental health disorders and related medication use of youth with JIA or IBD at a tertiary care centre. Methods: We conducted a retrospective chart review of youths aged 12–17 diagnosed with JIA or IBD at McMaster Children’s Hospital (MCH) to understand the prevalence of generalized anxiety disorder (GAD), separation anxiety disorder, social anxiety disorder (SAD), obsessive–compulsive disorders (OCD), eating disorders, major depressive disorder (MDD), adolescent adjustment disorder, suicide attempt/suicide ideation, self-harm behaviour, substance use disorder, and attention deficit disorders (ADD). Results: We reviewed 429 patient charts, including 303 patients with IBD and 126 with JIA. Our findings identified 90 IBD patients and 20 JIA patients who had one or more documented mental health conditions. Proportionately, there was a higher prevalence of mental health conditions among IBD patients (30%) compared to JIA patients (16%). The most frequently observed conditions in both IBD and JIA patients were GAD (63%, 50%), ADD (33%, 35%), and MDD (29%, 15%). Conclusions: These findings highlight the critical need for early mental health screening and integrated care approaches that address both medical and psychosocial needs in adolescents with chronic illnesses. Future research should incorporate prospective study designs, include diverse geographic and demographic populations, and explore targeted interventions to improve mental and physical health outcomes in this vulnerable group.
Open AccessSilent Struggles: Uncovering Mental Health Burdens in Adolescents with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis—A Retrospective Chart Review
Background/Objectives: Juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) are chronic autoimmune conditions that impact the physical and psychological well-being of pediatric patients. While previous studies have shown a high prevalence of mental health challenges among youth with chronic conditions, the prevalence of mental health issues in Canadian pediatric patients with JIA and IBD remains unclear. We aimed to estimate the prevalence of documented mental health disorders and related medication use of youth with JIA or IBD at a tertiary care centre. Methods: We conducted a retrospective chart review of youths aged 12–17 diagnosed with JIA or IBD at McMaster Children’s Hospital (MCH) to understand the prevalence of generalized anxiety disorder (GAD), separation anxiety disorder, social anxiety disorder (SAD), obsessive–compulsive disorders (OCD), eating disorders, major depressive disorder (MDD), adolescent adjustment disorder, suicide attempt/suicide ideation, self-harm behaviour, substance use disorder, and attention deficit disorders (ADD). Results: We reviewed 429 patient charts, including 303 patients with IBD and 126 with JIA. Our findings identified 90 IBD patients and 20 JIA patients who had one or more documented mental health conditions. Proportionately, there was a higher prevalence of mental health conditions among IBD patients (30%) compared to JIA patients (16%). The most frequently observed conditions in both IBD and JIA patients were GAD (63%, 50%), ADD (33%, 35%), and MDD (29%, 15%). Conclusions: These findings highlight the critical need for early mental health screening and integrated care approaches that address both medical and psychosocial needs in adolescents with chronic illnesses. Future research should incorporate prospective study designs, include diverse geographic and demographic populations, and explore targeted interventions to improve mental and physical health outcomes in this vulnerable group.
- 22 October 2019
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 44 (6) , 1112-1123
Starving the Gut: A Deficit of Butyrate in the Intestinal Ecosystem of Children With Intestinal Failure
Background: Intestinal epithelial integrity is influenced by short‐chain fatty acids (SCFAs) and is of critical importance for children with intestinal failure (IF) given the known devastating infectious and gastrointestinal complications. The composition of the microbiome in IF represents an important variable in the physiology and prognosis of this disease.Aim: We sought to compare the intestinal microbiome and SCFA concentration of children who require parenteral nutrition (PN) with that of children with short‐bowel syndrome (SBS) who have discontinued PN and with age‐matched controls, using high‐throughput sequencing to investigate host‐microbe interactions.Methods: Fifty‐three samples were submitted over 6–15 months. Six children with SBS + IF submitted 34 samples, and 6 children with SBS with discontinued PN submitted 15 samples; these were compared with samples from 5 control children. Fecal samples were analyzed by 16S ribosomal RNA partial gene sequencing using the MiSeq Illumina sequencer. SCFAs were measured in stool samples by mass spectrometry.Results: Butyrate quantity was near absent in children with IF compared with that in controls (median 0.37 nmol/mg vs 10.92 nmol/mg; P < .0001). Similarly, commensal anaerobes known to produce SCFA, including Ruminococcaceae and Lachnospiraceae, were reduced in those with SBS. SBS + IF enteric samples demonstrated a 168‐fold increase in the relative abundance of the Escherichia genus seemingly attributable to the species Escherichia coli.Conclusion: The reduced relative abundance of butyrate‐producing Clostridia as well as decreased intestinal butyrate concentration in children with IF support further investigation in therapeutic options that target butyrate‐producing bacterial communities or butyrate supplementation.
- 22 October 2019
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 44 (6) , 1112-1123
Starving the Gut: A Deficit of Butyrate in the Intestinal Ecosystem of Children With Intestinal Failure
Background: Intestinal epithelial integrity is influenced by short‐chain fatty acids (SCFAs) and is of critical importance for children with intestinal failure (IF) given the known devastating infectious and gastrointestinal complications. The composition of the microbiome in IF represents an important variable in the physiology and prognosis of this disease.Aim: We sought to compare the intestinal microbiome and SCFA concentration of children who require parenteral nutrition (PN) with that of children with short‐bowel syndrome (SBS) who have discontinued PN and with age‐matched controls, using high‐throughput sequencing to investigate host‐microbe interactions.Methods: Fifty‐three samples were submitted over 6–15 months. Six children with SBS + IF submitted 34 samples, and 6 children with SBS with discontinued PN submitted 15 samples; these were compared with samples from 5 control children. Fecal samples were analyzed by 16S ribosomal RNA partial gene sequencing using the MiSeq Illumina sequencer. SCFAs were measured in stool samples by mass spectrometry.Results: Butyrate quantity was near absent in children with IF compared with that in controls (median 0.37 nmol/mg vs 10.92 nmol/mg; P < .0001). Similarly, commensal anaerobes known to produce SCFA, including Ruminococcaceae and Lachnospiraceae, were reduced in those with SBS. SBS + IF enteric samples demonstrated a 168‐fold increase in the relative abundance of the Escherichia genus seemingly attributable to the species Escherichia coli.Conclusion: The reduced relative abundance of butyrate‐producing Clostridia as well as decreased intestinal butyrate concentration in children with IF support further investigation in therapeutic options that target butyrate‐producing bacterial communities or butyrate supplementation.